公开(公告)号：US20210069157A1

公开(公告)日：2021-03-11

申请号：US16323374

申请日：2017-02-24

Applicant: Kowa Company, Ltd

Inventor： Mitsumasa NAKAMURA ,  Satoshi Kojima ,  Ryohei Tanigawa

IPC: A61K31/423 ,  A61P1/16

Abstract: The present invention relates to a pharmaceutical composition for the treatment of primary biliary cirrhosis (PBC), in which containing a therapeutically effective amount of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate thereof.

公开(公告)号：US11419854B2

公开(公告)日：2022-08-23

申请号：US16609249

申请日：2018-06-29

Applicant: KOWA COMPANY, LTD.

Inventor： Satoshi Kojima ,  Ryohei Tanigawa

IPC: A61K31/423 ,  A61P1/16 ,  A61P3/06 ,  A61P3/10 ,  A61P9/00 ,  A61P9/10 ,  A61P43/00

Abstract: To provide an appropriate method of treatment with pemafibrate for a liver cirrhosis patient.
The present invention relates to the use of pemafibrate in a liver cirrhosis patient.
More particularly, the present invention relates to a regimen for administering a reduced dose of pemafibrate to a liver cirrhosis patient in need of treatment with pemafibrate than to persons with normal liver function.

公开(公告)号：US10314825B2

公开(公告)日：2019-06-11

申请号：US15903279

申请日：2018-02-23

Applicant: KOWA COMPANY, LTD.

Inventor： Mitsumasa Nakamura ,  Satoshi Kojima ,  Ryohei Tanigawa

IPC: A61K31/423 ,  A61P1/16 ,  A61K31/575

Abstract: The present invention relates to a pharmaceutical composition for the treatment of primary biliary cirrhosis (PBC), in which containing a therapeutically effective amount of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate thereof.